At $446.3 million in gross proceeds, RNA-focused Adarx Pharmaceuticals Inc.’s IPO represents the fourth largest biopharma ...
Remynd NV is back on track with its novel septin-targeting Alzheimer’s disease program after addressing liver toxicity ...
The value of biopharma deals has generally trended upward, despite year-over-year and month-to-month volatility. BioWorld’s ...
At the International Myeloma Society meeting, Brightpath Biotherapeutics Co. Ltd. presented data for BP-2202, an ...
New collaborations involving Henlius, Amberstone, Sanyou Bio and Novocodex highlight efforts to improve the safety, precision ...
Acadia Pharmaceuticals Inc.’s near miss disclosed Sept. 24 in phase II with 5HT2A receptor inverse agonist remlifanserin in ...
Eli Lilly and Co. has struck another major China partnership, signing a discovery-stage collaboration with Beijing-based ...
Finnish newco Kasvu Therapeutics has raised €30 million (US$34.4 million) in a series A financing to take forward novel small ...
Cellular senescence is commonly associated with aging, but it also plays essential roles during embryonic development.
Sotio Biotech AS’s SOT-106 has been awarded orphan drug designation by the FDA for the treatment of soft tissue sarcoma and ...
Xtalpi Inc. has submitted an IND application to the FDA for KQTD-126, a gut-restricted pan-TRK inhibitor designed to treat chronic intestinal pain associated with irritable bowel syndrome and ...
In a continuous effort to improve its cardiometabolic franchise, Novo Nordisk A/S entered a deal worth up to €1.165 billion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results